These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11473030)

  • 21. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
    Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
    Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways.
    Nishizawa M; Nakabayashi H; Uehara K; Nakagawa A; Uchida K; Koya D
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(3):E376-87. PubMed ID: 23715725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
    Hvidberg A; Nielsen MT; Hilsted J; Orskov C; Holst JJ
    Metabolism; 1994 Jan; 43(1):104-8. PubMed ID: 8289665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
    Ionut V; Castro AV; Woolcott OO; Stefanovski D; Iyer MS; Broussard JL; Burch M; Elazary R; Kolka CM; Mkrtchyan H; Bediako IA; Bergman RN
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E644-52. PubMed ID: 25117408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
    Prigeon RL; Quddusi S; Paty B; D'Alessio DA
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
    Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
    Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
    Orskov L; Holst JJ; Møller J; Orskov C; Møller N; Alberti KG; Schmitz O
    Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
    Toft-Nielson M; Madsbad S; Holst JJ
    Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Importance of the hepatic arterial glucose level in generation of the portal signal in conscious dogs.
    Hsieh PS; Moore MC; Neal DW; Cherrington AD
    Am J Physiol Endocrinol Metab; 2000 Aug; 279(2):E284-92. PubMed ID: 10913027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
    Baggio LL; Kim JG; Drucker DJ
    Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice.
    Burcelin R; Dolci W; Thorens B
    Diabetes; 2000 Oct; 49(10):1643-8. PubMed ID: 11016447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.
    Baggio L; Kieffer TJ; Drucker DJ
    Endocrinology; 2000 Oct; 141(10):3703-9. PubMed ID: 11014225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.